141 Human Immunodeficiency Virus Infection
Many changes have occurred in the overall management and prognosis of patients with human immunodeficiency virus (HIV). Management of HIV-infected patients early in the acquired immunodeficiency syndrome (AIDS) epidemic was based largely on the diagnosis and treatment of opportunistic infections and neoplasms. Because these disorders were diagnosed late in the course of HIV infection, treatment often yielded poor results. In 1987, the first antiretroviral medication, zidovudine, became available and was followed by other nucleoside analogs.1–2 In concert with chemoprophylaxis for opportunistic infections, these agents offered the first hope that HIV infection could be slowed. As time has passed, other classes of medications have been developed to combat HIV. With the discovery of protease inhibitors and the use of combination antiretroviral therapy (ART), there has been dramatic improvement in the morbidity and mortality of patients infected with HIV.3 These combinations of medications can result in prolonged suppression of HIV viral RNA levels and sustained increases in CD4 cell counts.
Changes in the clinical characteristics and survival of those patients with HIV admitted to an intensive care unit (ICU) have occurred since the widespread introduction of combination ART in 1996. Unfortunately, not all patients have been able to benefit from antiretroviral therapy. Those not known to be HIV-infected, those without access to medications, and those not responding to antiretroviral therapy may still present with AIDS-associated opportunistic infections and neoplasms.4 In this chapter, we discuss recent trends in the epidemiology and survival of HIV-infected patients admitted to an ICU. Because Pneumocystis carinii pneumonia (PCP) remains a leading cause of respiratory failure in HIV-infected patients and still carries a high mortality rate in the ICU, we will also discuss diagnostic approaches and therapy for PCP. Finally, we will examine problems unique to the ICU care of HIV-infected patients, particularly those related to combination ART.
Intensive Care Trends Among HIV-Infected Patients
Epidemiology
Both the epidemiology of ICU admissions and views of the utility of ICU care for HIV-infected patients have undergone several shifts during the course of the AIDS epidemic. In the beginning of the epidemic, most patients with HIV infection admitted to the ICU had PCP, and survival was poor.5 ICU admission was often considered futile. Over the course of the epidemic, bacterial pneumonia, sepsis, and non–HIV-associated diagnoses have become increasingly common, although PCP remains an important cause of ICU admission, with high mortality in certain groups of patients. With the widespread availability of combination ART, there have been continued changes in ICU mortality and epidemiology so that ICU care is again indicated for most patients. Unfortunately, with reports of antiretroviral resistance and transmission of multidrug-resistant HIV, ICU trends may shift again, with an increase in opportunistic infections and poor outcomes.6–8
The most extensive series documenting ICU epidemiology has come from San Francisco General Hospital where researchers have tracked the trends in ICU diagnoses, admissions, and survival throughout the different eras of the AIDS epidemic. During era I (1981-1985), overall hospital mortality for those admitted to an ICU was 69%, and median survival was only 7 months.5 The number of ICU admissions peaked in 1984 and then decreased despite rising numbers of hospital admissions for AIDS patients. This decrease in ICU admissions was attributed to both physicians’ and patients’ views of ICU care as futile. In era II (1986-1988), mortality decreased, largely as a result of the use of adjunctive corticosteroids for PCP, which was still the leading cause of ICU admission.9 Era III (1989-1991) actually saw an increase in mortality rates for PCP, likely from a bias away from withholding or withdrawing care.10 In era IV (1992-1995), rates of ICU admission remained stable, and overall mortality was 36.9%, a significant improvement from era I.11
Era V, or the era of combination ART (1996-1999), brought about significant changes in both mortality and admission rates.12 The number of ICU admissions decreased significantly from an average of 111 per year in era IV to 88.5 per year in era V, and survival rate increased to 71%. Respiratory failure was still the most common cause of ICU admission (40.7% of diagnoses), but PCP only accounted for 10.7% of admissions compared with 17.6% in era IV. Admission demographics of patients reflected national trends in the HIV epidemic. During previous eras, the majority of patients were white homosexual men.11 During era V, African-Americans accounted for 44.6% of persons admitted to the ICU, and women and intravenous (IV) drug users were also more commonly admitted. During era VI (2000-2004), survival was about 69% over the entire period, with survival ratios increasing yearly during that time period from 58% in 2000 to 75% in 2004 (P = 0.001).13 In addition, while PCP was the most common cause of respiratory failure in patients not on ART, obstructive airways disease was the most common cause of respiratory failure among patients on ART.13
Exact mortality and admission rates are different in different centers, but overall trends of decreasing mortality and changes in the spectrum of diagnoses related to HIV remain similar. A recent French study described the etiology and outcome of acute respiratory failure in HIV-infected patients from 1996 to 2000. Overall survival was 80% in this series.14 In a British study examining 102 patients between 1999 and 2005, ICU and hospital discharge rates in HIV-infected patients were 77% and 68%, respectively, and no different than non–HIV-infected patients.15 A study in Brazil of all HIV-infected ICU patients admitted between 1996 and 2006 found an ICU mortality of 55% and a 6-month mortality of 69%, and the authors postulated that their higher mortality rate was due to differences in patient characteristics and ICU access in their country.28
In most series, respiratory failure remains the leading cause of ICU admission in HIV-infected patients, although the percentage of respiratory admissions has declined. PCP accounted for as many as 62% of all ICU admissions in the early days of the epidemic and was by far the most common cause of respiratory failure.5 Since the advent of ART, bacterial pneumonia has become more common, although PCP still accounts for many cases of respiratory failure.13–16 In the ART era, Casolino reported an increase in ICU admissions for severe sepsis, often associated with respiratory failure (P = 0.03).17 HIV-infected patients with bacterial pneumonia are more likely to become bacteremic, and mortality may be as high as 68% in this setting.18 Non–AIDS-related diagnoses such as myocardial infarction, airways obstruction, and trauma are becoming more common during the current era of ART, as are ART-associated diagnoses.
In addition to respiratory failure, other comorbid conditions associated with HIV infection may be seen on admission to the ICU. These include cardiac disease, end-stage liver disease, and HIV-related renal disease. Combination ART has been associated with metabolic syndrome, dyslipidemias, and increased risk of myocardial infarction.19–21 End-stage liver disease due to viral hepatis and HIV co-infection is a significant nonrespiratory problem seen in HIV-infected patients admitted to the ICU. Due to similar mechanisms of infection, chronic hepatitis B virus (HBV) has been reported in 10% and chronic hepatitis C virus (HCV) in 25% of HIV-infected individuals.22 It is not clear whether HIV alters the course of HBV infection; however, HIV is a known risk factor for the accelerated progression of HCV to cirrhosis.23 In addition to hepatotoxicity from hepatitis co-infection, many antiretrovirals can also elevate transaminase levels.24 Finally, end-stage renal disease (ESRD) secondary to HIV is also a common complication. Although the prevalence has also decreased with the development of combination ART, it remains a significant problem, especially in HIV-infected African Americans, who are at higher risk of developing HIV-associated nephropathy with progression to ESRD.25,26 Other risk factors for progression of chronic kidney disease include comorbidities such as hypertension, diabetes, HCV co-infection, and ART.27
Prognostic Factors
Clinicians and patients making decisions regarding the utility of care should understand risk factors for ICU mortality among HIV-infected patients. Studies have shown that there are several key factors that influence mortality, and these factors seem not to have changed over the years. Multivariate analysis of the cohort from era V at San Francisco General Hospital demonstrated that mechanical ventilation or a diagnosis of PCP predicted a higher mortality rate, whereas admission for a non–AIDS-associated diagnosis, an albumin level greater than 2.6 g/dL, and an Acute Physiology and Chronic Health Evaluation (APACHE) II score less than 13 all were associated with an increase in survival to hospital discharge.12 These factors—particularly mechanical ventilation, vasopressor use, serum albumin, and PCP—had been known to influence mortality before the ART era as well.11,14,17 In the cohort from era VI at San Francisco General Hospital, lack of invasive mechanical ventilation and albumin level were associated with improved survival to hospital discharge.13 A recent study found that a CD4 cell count below 50 cells/µL is associated with ICU mortality and sepsis, and APACHE score above 19, need for mechanical ventilation during the first 24 hours of ICU admission, and year of ICU admission were associated with 6-month mortality.28 Other long-term mortality predictors include an AIDS diagnosis before admission or first AIDS-defining condition.17
Intensive Care Trends in Pneumocystis Pneumonia
Because PCP has historically been the most common cause of respiratory failure in AIDS patients and the most common reason for ICU admission, more is known about the outcome of intensive care for AIDS patients with PCP than for any HIV-infected group. Mortality for PCP in the ICU, particularly for patients requiring mechanical ventilation, has been high throughout the course of the AIDS epidemic, but there have been some improvements. In the 1980s, HIV patients with PCP who required intensive care had a mortality rate as high as 81%, and mortality for patients requiring mechanical ventilation was 87%.5 The introduction of adjunctive corticosteroids in the mid-1980s improved mortality for PCP-associated respiratory failure to approximately 60%.9,29,30
Mortality due to PCP has continued to decline in the era of combination ART. In a study of 59 consecutive patients admitted to the ICU, Miller and colleagues reported a 71% mortality prior to mid-1996, which decreased to 34% thereafter (P = 0.008).31 In addition to year of diagnosis, risk factors associated with death also included age (odds ratio [OR], 19.76; 95% confidence interval [CI], 1.74-224.34; P = 0.016) and mechanical ventilation and/or pneumothorax (OR, 5.18; 95% CI, 1.16-23.15; P = 0.031). In another large cohort study, Walzer and colleagues performed a retrospective study of HIV-infected adults admitted to the hospital with confirmed PCP between 1985 and 2006 and reported an overall mortality of 13.5%.32 Risk factors associated with mortality included age 50 years or older, prior history of PCP, low hemoglobin level, PaO2 less than 8.0 kPa on admission, pulmonary Kaposi sarcoma, and presence of a medical comorbidity. This study excluded complications subsequent to admission such as need for mechanical ventilation, pneumothorax, ICU admission, and treatment failure.32
Although there has been improvement in PCP survival in the era of combination ART, a diagnosis of PCP still remains a risk factor for overall mortality.13,33 In a retrospective cohort study of 148 consecutive HIV-infected adults admitted to the ICU with respiratory failure, PCP was associated with increased risk of in-hospital mortality (OR, 3.19; 95% CI, 1.15-8.89; P = 0.029).33
Diagnosis and Treatment of Pneumocystis Pneumonia
Clinical Presentation
Although the number of cases of PCP has decreased, it remains a leading cause of respiratory failure among HIV-infected patients. PCP most commonly occurs in patients with CD4 cell counts below 200 cells/µL, and the risk of PCP increases exponentially as the CD4 cell count decreases below that level.34,35 The clinical presentation of PCP ranges from the subtle to the fulminant. Most patients have most or all of the following symptoms and signs: fever, tachypnea, dyspnea with a nonproductive cough, and a chest examination that is normal or has a few dry rales.36,37 In the HIV-infected patient, symptoms have generally been present for days to weeks before the diagnosis is made. Many patients may not be known to be HIV-infected. Recent studies have shown that approximately two-thirds of patients admitted to the ICU with PCP are unaware they are infected with HIV,31,32 so clinicians must remember to include PCP in their differential of respiratory failure, even in those patients not known to have HIV.
Severe PCP is often similar in presentation and pathogenesis to acute respiratory distress syndrome (ARDS). The organism appears to cause a widespread capillary leak, and the chest radiograph usually resembles that in ARDS, with diffuse bilateral interstitial infiltrates. Less commonly, PCP results in focal airspace consolidation. Infiltrates are occasionally unilateral or asymmetrical, and the pattern seen (interstitial and nodular) is more suggestive of the diagnosis than the distribution of the abnormalities.38 Finally, about 10% to 15% of patients who prove to have PCP initially have normal chest radiographs.39,40
Diagnosis
Although PCP may have a typical clinical and radiographic presentation, definitive diagnosis is encouraged, particularly in those who are critically ill. Many respiratory diseases in HIV have overlapping presentations, and prompt initiation of appropriate therapy is important to prevent clinical deterioration and avoid unnecessary drug side effects. The diagnosis of PCP is made when the organism is identified in the pulmonary secretions of a patient with a compatible clinical presentation. PCP may be diagnosed by examination of induced sputum, which has a sensitivity of 79% and a negative predictive value of 61% in experienced hands.41 The usefulness of sputum induction is often limited because many hospitals may not be experienced in performing the test, and sputum induction is generally not tolerated in patients with respiratory distress.
When the sputum examination is negative or when it is not possible to obtain induced sputum, bronchoscopy with bronchoalveolar lavage (BAL) is the procedure of choice, with a sensitivity of over 90% for diagnosis of PCP in an HIV-infected individual and even greater yield when bilateral sampling is performed.42,43 Bronchoscopy with BAL should be performed as early as possible in undiagnosed patients. Although the addition of transbronchial biopsy generally adds little to the yield of lavage in the diagnosis of HIV-associated PCP, it can be helpful in HIV-infected patients with other pulmonary processes.44 Transbronchial biopsy is thus a reasonable initial invasive study when the probability of PCP is low and the risks associated with the procedure are acceptable; it is a useful follow-up test when the BAL fails to demonstrate PCP.
Treatment
A summary of treatment regimens in decreasing order of preference is given in Table 141-1. The treatment of choice for moderate to severe PCP is IV trimethoprim-sulfamethoxazole (TMP-SMX).37 In a retrospective study of 1122 patients with PCP, comparison of 3-month survival rates between TMP-SMX, clindamycin-primaquine and IV pentamidine were 85%, 81%, and 76% (P = 0.09), respectively.45 The TMP-SMX should be administered at a total daily dose of 15 to 20 mg/kg of trimethoprim and 75 to 100 mg/kg of sulfamethoxazole divided into 3 or 4 doses per day; recommended duration of therapy is 21 days.37 Approximately 25% of patients will have therapy-limiting toxicity from TMP-SMX, with most severe toxicities occurring between days 6 and 10 of treatment.46–49 Side effects of TMP-SMX include nausea, rash, bone marrow suppression, hyponatremia, hyperkalemia, renal dysfunction, and transaminitis.
TABLE 141-1 Treatment Regimens for Severe Pneumocystis Pneumonia in Decreasing Order of Preference
| Agent | Dose | Side Effects |
|---|---|---|
| Trimethoprim-sulfamethoxazole | trimethoprim, 15-20 mg/kg/d, with sulfamethoxazole, 75-100 mg/kg/d IV, divided q 6-8 h | Rash, nausea, bone marrow suppression, hyponatremia, hyperkalemia, nephrotoxicity, transaminitis |
| Pentamidine isethionate | 3-4 mg/kg/d IV | Nausea, hypotension, hypoglycemia or hyperglycemia, pancreatitis, bone marrow suppression, nephrotoxicity |
| Clindamycin-primaquine | clindamycin, 900 mg IV q 8 h; primaquine, 30 mg PO daily | Nausea, diarrhea, rash, hemolytic anemia, methemoglobinemia, leukopenia |
| Adjunctive therapy: | ||
| Prednisone if PaO2 <70 mm Hg or alveolar-arterial gradient >35 mm Hg | 40 mg PO q 12 h for 5 days, 40 mg PO daily for 5 days, 20 mg PO daily for 11 days |
Hyperglycemia, psychosis |
Intravenous pentamidine isethionate is an effective alternative for therapy in patients who cannot tolerate TMP-SMX or have failed treatment.37 Although this agent has been reported to have success rates equivalent to TMP-SMX, some studies have found that it is somewhat less efficacious.45,50–52 The recommended daily dose of pentamidine is 3 to 4 mg/kg administered over 1 hour. Pentamidine has a high rate of serious toxicity that includes nausea, hypotension, pancreatitis, hypoglycemia and hyperglycemia, bone marrow suppression, and nephrotoxicity. Because pentamidine is toxic to the pancreatic islet cells, initial hypoglycemia from a surge of insulin release followed by hyperglycemia from inadequate insulin may be seen, and the patient may progress to chronic diabetes mellitus. Adverse reactions may be seen in as many as 50% of patients treated with pentamidine.
Second-line therapy may be used if first-line therapies prove to be ineffective or have unacceptable side effects. Because treatment of PCP is often accompanied by an initial worsening, treatment failure should not be diagnosed before 4 to 8 days of therapy. If TMP-SMX has been the first-line agent, IV pentamidine or the combination of IV clindamycin with oral primaquine may be substituted. Recent studies of second-line regimens found that TMP-SMX and clindamycin-primaquine had equivalent success rates, but response to pentamidine was significantly lower.45,53 These studies included both ICU and non-ICU patients, and the lower response rate seen with pentamidine may have resulted from in an increased tendency to use IV pentamidine in ICU patients, because oral absorption of primaquine may be poor in this population.
The most profound improvement in PCP mortality has occurred with the introduction of adjunctive corticosteroids.9,29,30 In a meta-analysis of six randomized controlled trials comparing adjunctive corticosteroids to standard care in HIV-infected patients with PCP, risk ratios for overall mortality were 0.54 (95% CI, 0.38-0.79) at 1 month and 0.67 (95% CI, 0.49-0.93) at 3 to 4 months in favor of corticosteroids. In patients undergoing mechanical ventilation, corticosteroids were also associated with an improved outcome (risk ratio of 0.37; 95% CI, 0.20-0.70).54 It is recommended that patients with PCP and either a PaO2 in room air of less than 70 mm Hg or an alveolar-arterial oxygen gradient greater than 35 mm Hg receive corticosteroids to reduce mortality.37 Corticosteroid therapy should be administered within 72 hours of initiating anti-Pneumocystis therapy, even if the diagnosis has not yet been established, because corticosteroids act to decrease the inflammation seen during the first few days of treatment. The recommended regimen is oral prednisone, 40 mg, given twice daily for 5 days, followed by 40 mg once daily for 5 days, then 20 mg daily for 11 days. For those patients unable to take oral medications, IV methylprednisolone may be substituted at 75% of the prednisone dose.37
Treatment Failure
Given that patients’ conditions may deteriorate and that symptoms may be prolonged, it is difficult to determine when a treatment regimen is failing and should be abandoned for an alternative. Whether treatment failure is more likely in patients with previous prophylaxis use is unknown, but Pneumocystis has been shown to develop genetic mutations with exposure to sulfa- or sulfone-containing medications such as TMP-SMX and dapsone.55,56 The relationship of these mutations to outcome is still controversial.57–60 In general, treatment should be continued for 4 to 8 days before considering changing to a different agent.37 It is also important to investigate alternative diagnoses that may be responsible for the patient’s symptoms. Other causes of pneumonia including other opportunistic pathogens and nosocomial organisms should be considered when treatment appears to be failing. Patients with PCP are also at increased risk of pulmonary edema, which may explain worsening respiratory status with increasing radiographic infiltrates. Alternative diagnoses should be pursued with chest computed tomography (CT), sputum cultures, or echocardiography as clinically indicated. Repeat bronchoscopy is helpful to diagnose agents other than PCP, but is not useful in determining whether PCP treatment is failing, because Pneumocystis may persist in the bronchoalveolar lavage fluid for several weeks.61
Ventilation of the Patient with PCP
The physiology of severe PCP resembles that of ARDS, and patients with PCP are at high risk for developing barotrauma and pneumothoraces, often heralding a fatal outcome. Low tidal volume ventilation per ARDSNet protocol has been shown to be associated with decreased mortality in HIV-infected patients with acute lung injury (OR, 0.76 per 1 mL/kg decrease; 95% CI, 0.58-0.99, P = 0.043).33,62 Similar to non–HIV-infected patients with acute lung injury (ALI), low tidal volume ventilation is becoming the standard of care in HIV-infected patients with ALI from PCP or other causes. Noninvasive positive-pressure ventilation (NIPPV) has been studied in PCP and has been found to lower the rate of intubation, decrease the incidence of pneumothorax, and improve ICU survival.63 Use of NIPPV would be a reasonable first-line ventilation mode in patients with PCP and respiratory distress who can tolerate this form of ventilation and who can protect their airway.
Combination Antiretroviral Therapy and the ICU
Lactic Acidosis
With the increasing use of combination ART, ICU physicians need to be familiar with some of the life-threatening side effects that can occur with these medications. The syndrome of severe hepatic steatosis and lactic acidosis was first described in the 1990s.64,65 The syndrome is most commonly associated with nucleoside reverse transcriptase inhibitors (NRTIs), particularly didanosine and stavudine, and results from mitochondrial toxicity of these agents.66,67 The incidence of hyperlactatemia in patients taking NRTIs has been reported as high as 227 cases per 1000 person-years.68 Symptomatic lactic acidosis in HIV-infected patients taking NRTIs ranges from 1 to 25.2 cases per 1000 patient-years, and mortality rates may be as high as 77%.69 Risk factors for development of hyperlactatemia include older age, drug regimens containing stavudine or combined stavudine-didanosine, use of buprenorphine, creatinine clearance less than 70 mL/min, and nadir CD4 cell count less than 250 cells/µL.70,71 A case-control study indicated that female sex and obesity were also risk factors for stavudine-related lactic acidosis.70
Patients often present with abdominal pain, nausea, and vomiting and may have myalgias or peripheral neuropathies. Serum lactate levels are elevated, and hepatic steatosis and elevation of transaminases occur frequently. Often, cessation of the ART results in resolution of the syndrome; however, some patients can progress to life-threatening organ failure. An initial lactate level above 9 mmol/L seems to be associated with a higher risk of death, and some authors believe that a level greater than 5 mmol/L should be considered life threatening.72,73
In patients presenting with mild lactic acidosis, the offending agent should be switched to a safer alternative (e.g., abacavir, tenofovir, lamivudine, emtricitabine). Lactate levels should be closely monitored after changing the NRTI. For severe lactate acidosis, ART should be discontinued, and supportive care should be administered.24 Although data regarding treatment outcomes are not extensive, treatment should be started in those patients with a lactate level above 5 mmol/L. Treatment with riboflavin, thiamine, and L-carnitine has reversed toxicity in some case reports.24,72–75 One recommended regimen is to administer 50 mg of riboflavin daily with 50 mg/kg of L-carnitine and 100 mg of thiamine until the lactic acidosis resolves. The exact length of treatment and the lactate level above which treatment is unlikely to succeed remain unclear.
Immune Reconstitution
The immune reconstitution inflammatory syndrome (IRIS) leads to paradoxical worsening of an infection shortly after initiation of ART. This syndrome results from improvement in the immune system and a renewed inflammatory response directed against infectious agents.76 Although this syndrome has been reported to occur in diseases such as tuberculosis, cytomegalovirus (CMV), and Mycobacterium avium complex, it usually results only in a symptomatic worsening of these conditions.76–78 A recent meta-analysis of 54 cohort studies of patients who developed IRIS found that IRIS occurred in 16.1% (95% CI, 11.1-22.9) of all patients and was associated with a 4.5% (95% CI, 2.1-8.6) mortality.79 There have been case reports of paradoxical worsening occurring during PCP, with patients experiencing increasing respiratory distress and hypoxemia and some requiring mechanical ventilation.80–82 All patients subsequently recovered, and there seemed to be some benefit from continuing or reintroducing corticosteroids.82 Patients admitted to the ICU with a presumed paradoxical worsening of PCP should receive corticosteroids, and appropriate testing should be performed to rule out other infections or respiratory disorders causing clinical worsening.
Administration of Antiretroviral Therapy in the Icu
ART therapy is complicated in the ICU. Only zidovudine is available in an IV form. Other agents that are available as liquids and therefore could be administered via a feeding tube are listed in Box 141-1. If physicians choose to administer ART to an ICU patient, they need to be particularly aware of possible side effects including renal toxicity and hepatotoxicity, pancreatitis, and lactic acidosis. Many common ICU medications such as benzodiazepines, fluconazole, pentamidine, and amiodarone may have dangerous interactions or altered metabolism when given with antiretrovirals. Medications may also affect the serum levels of antiretrovirals, resulting either in toxic or subtherapeutic concentrations. Consultation with a specialist familiar with the many antiretroviral regimens is advised.
Box 141-1
List of Antiretroviral Agents Available in Non–Pill Form
It is currently unclear whether the mortality benefits of ART administration in ICU patients outweigh the risks and difficulties. Although not limited to critically ill patients, results from a recent randomized controlled trial compared deferring therapy to initiating ART within 14 days of starting therapy for an AIDS-related opportunistic infection or serious bacterial infection; early ART resulted in decreased progression of AIDS or death compared to deferred therapy (OR, 0.51; 95% CI, 0.27-0.94).83 In a retrospective cohort study of 278 HIV-infected patients admitted to the ICU in Sao Paolo from 1996 through 2006, Croda and colleagues found beginning ART during the ICU stay was associated with reduced 6-month mortality, significantly less than patients not on ART while in the ICU (hazard ratio, 0.55; 95% CI, 0.31-0.98; P = 0.004).28 Survival was worse in those who were previously on ART and had it stopped while in intensive care; however, use of ART in the ICU was associated with adverse events in 18% of patients. Morris and colleagues studied patients with PCP admitted to the ICU during the era of ART. They found that mortality among patients who did not receive ART was 63%, whereas those patients either receiving ART at time of admission or started on ART in the ICU had a mortality rate of only 25%.84 There have been several reports of improved cumulative survival (e.g., months to years post ICU discharge) among ICU survivors started on ART.17,33,85–87 Other studies, however, have not found that starting ART in the ICU improves ICU or in-hospital survival.31,87 One study of HIV-infected patients with respiratory failure found a trend toward worse outcome in those receiving ART in the ICU (30% mortality in those on ART versus 15% in those not on ART, P = 0.07).14
Given the lack of consensus guidelines for whether and when to initiate combination ART in the ICU, the decision to do so must be made on a case-by-case basis. A useful treatment strategy was described by Huang and colleagues.88 In patients who are known to be HIV-positive and are already receiving combination ART, combination ART should be continued if the viral load is undetectable and there are no contraindications to continuing the drugs (e.g., drug toxicities, resistance, IRIS, difficulty in delivery or drug absorption). If the patient has a contraindication to ART, the entire regimen should be held so as not to foster resistance, and an HIV specialist should be consulted. In patients who are known to be HIV positive but are not on ART, or who are diagnosed with HIV on their ICU admission, consideration should be given to starting combination ART if the condition is an AIDS-associated condition, and an HIV specialist should be consulted. If the condition is not AIDS-associated, and CD4 count is greater than 200 cells, ART should probably be deferred until after the patient is discharged from the ICU, unless their ICU course is prolonged. The importance of consultation with an HIV specialist in these ART treatment decisions cannot be overemphasized.
Metabolic Abnormalities in the ICU
Metabolic Complications of Antiretroviral Therapy
Many drugs included in ART regimens have adverse effects on the metabolism of lipids and glucose. Patients treated with these drugs commonly develop metabolic abnormalities including hyperlipidemia, hypercholesterolemia, glucose intolerance, and diabetes.89–91 Conditions such as cardiovascular disease, dyslipidemia, insulin resistance, and osteoporosis seem to be associated with ART, and protease inhibitors have been specifically associated with an increased relative risk of myocardial infarction (MI).19,20,92 The HIV Outpatient Study (HOPS) found that risk of MI increased among those using protease inhibitors (OR for MI = 7.1).93 In the landmark multicenter prospective study of 23,468 patients, the Data Collection on Adverse Events of Anti-HIV Drugs (DAD) study group reported that combination ART was independently associated with a 26 percent relative increase in the rate of MI per year of exposure in the first 4 to 6 years of use.20 In a follow-up study, the group showed that exposure to protease inhibitors was associated with increased risk of MI, likely related to dyslipidemia.19 More recent studies have reported that the nucleoside reverse transcriptase inhibitors, abacavir and didanosine, are also associated with increased risk of cardiovascular disease,94,95 but not all studies support this association. A cohort of over 36,000 HIV-infected patients followed from 1993 to 2001 demonstrated no relationship between use of antiretroviral medications and cerebrovascular or cardiovascular events, but follow-up may have been too short to detect an effect.96 In general, HIV-infected patients admitted to the ICU with cardiac disease should be treated as the non–HIV-infected population, with interventions including cardiac artery bypass grafting as indicated. Data show that short-term outcome is equivalent, although HIV-infected patients have a higher long-term risk of requiring revascularization.97 As HIV-infected patients live longer due to ART, clinicians can expect to see problems such as cardiac disease more frequently as the HIV-infected population ages.
Adrenal Insufficiency
Adrenal insufficiency is an important syndrome in the ICU that is more common among HIV-infected patients. The adrenal glands of patients with HIV may be damaged by infections such as CMV, neoplasms such as lymphoma, and drugs such as ketoconazole and rifampin.98–100 At its most severe, adrenal insufficiency can present as refractory hypotension and may lead to death if not recognized. Marik and colleagues studied adrenal function in 28 critically ill HIV-infected patients. In this study, depending on the criteria used, the rate of adrenal insufficiency varied from 7% to 75%.101 Evidence of CMV infection was more common among the patients with adrenal insufficiency. Clinicians should have a high degree of suspicion for adrenal insufficiency in HIV-infected patients, particularly in those with CMV, and should consider adrenocorticotropic hormone stimulation testing. Patients with septic shock or early ARDS should be empirically treated for adrenal insufficiency according to American College of Critical Care Medicine guidelines.102
ConclusionKey Points
Barbier F, Coquet I, Legriel S, et al. Etiologies and outcome of acute respiratory failure in HIV-infected patients. Intensive Care Med. 2009;35:1678-1686.
Casolino E, Wolff M, Ravaud P, et al. Impact of HAART advent on admission patterns and survival in HIV-infected patients admitted to an intensive care unit. AIDS. 2004;18:1429-1433.
Davis JL, Morris A, Kallet RH, et al. Low tidal volume ventilation is associated with reduced mortality in HIV-infected patients with acute lung injury. Thorax. 2008;11:988-993.
Dickson SJ, Batson S, Copas AJ, et al. Survival of HIV-infected patients in the intensive care unit in the era of highly active antiretroviral therapy. Thorax. 2007;62:964-968.
Muller M, Wandel S, Colebunders R, et al. Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect Dis. 2010;10:251-261.
Powell K, Davis JL, Morris AM, et al. Survival for patients with HIV admitted to the ICU continues to improve in the current era of combination antiretroviral therapy. Chest. 2009;135:11-17.
Walzer PD, Evans HE, Copas AJ, et al. Early predictors of mortality from Pneumocystis jirovecii pneumonia in HIV-infected patients: 1985-2006. Clin Infect Dis. 2008;46:625-633.
Zalopa A, Andersen J, Powderly W, et al. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PLoS One. 2009;4:e5575.
1 Fischl MA, Richman DD, Grieco MH, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med. 1987;317:185-191.
2 Kahn JO, Lagakos SW, Richman DD, et al. A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. The NIAID AIDS Clinical Trials Group. N Engl J Med. 1992;327:581-587.
3 Palella FJJr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338:853-860.
4 Kaplan JE, Hanson D, Dworkin MS, et al. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin Infect Dis. 2000;30(Suppl. 1):S5-14.
5 Wachter RM, Luce JM, Turner J, et al. Intensive care of patients with the acquired immunodeficiency syndrome. Outcome and changing patterns of utilization. Am Rev Respir Dis. 1986;134:891-896.
6 Yerly S, von Wyl V, Ledergerber B, et al. Transmission of HIV-1 drug resistance in Switzerland: a 10-year molecular epidemiology survey. AIDS. 2007;21:2223-2229.
7 Wensing AM, van de Vijver DA, Angarano G, et al. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis. 2005;192:958-966.
8 Little SJ, Holte S, Routy JP, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med. 2002;347:385-394.
9 Wachter RM, Russi MB, Bloch DA, et al. Pneumocystis carinii pneumonia and respiratory failure in AIDS. Improved outcomes and increased use of intensive care units. Am Rev Respir Dis. 1991;143:251-256.
10 Wachter RM, Luce JM, Safrin S, et al. Cost and outcome of intensive care for patients with AIDS, Pneumocystis carinii pneumonia, and severe respiratory failure. JAMA. 1995;273:230-235.
11 Nickas G, Wachter RM. Outcomes of intensive care for patients with human immunodeficiency virus infection. Arch Intern Med. 2000;160:541-547.
12 Morris A, Creasman J, Turner J, et al. Intensive care of human immunodeficiency virus-infected patients during the era of highly active antiretroviral therapy. Am J Respir Crit Care Med. 2002;166:262-267.
13 Powell K, Davis JL, Morris AM, et al. Survival for patients with HIV admitted to the ICU continues to improve in the current era of combination antiretroviral therapy. Chest. 2009;135:11-17.
14 Barbier F, Coquet I, Legriel S, et al. Etiologies and outcome of acute respiratory failure in HIV-infected patients. Intensive Care Med. 2009;35:1678-1686.
15 Dickson SJ, Batson S, Copas AJ, et al. Survival of HIV-infected patients in the intensive care unit in the era of highly active antiretroviral therapy. Thorax. 2007;62:964-968.
16 Alves C, Nicolas JM, Miro JM, et al. Reappraisal of the aetiology and prognostic factors of severe acute respiratory failure in HIV patients. Eur Respir J. 2001;17:87-93.
17 Casalino E, Wolff M, Ravaud P, et al. Impact of HAART advent on admission patterns and survival in HIV-infected patients admitted to an intensive care unit. AIDS. 2004;18:1429-1433.
18 Rosenberg AL, Seneff MG, Atiyeh L, et al. The importance of bacterial sepsis in intensive care unit patients with acquired immunodeficiency syndrome: implications for future care in the age of increasing antiretroviral resistance. Crit Care Med. 2001;29:548-556.
19 Friis-Moller N, Reiss P, Sabin CA, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007;356:1723-1735.
20 Friis-Moller N, Sabin CA, Weber R, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003;349:1993-2003.
21 Bonfanti P, Giannattasio C, Ricci E, et al. HIV and metabolic syndrome: a comparison with the general population. J Acquir Immune Defic Syndr. 2007;45:426-431.
22 Soriano V, Vispo E, Labarga P, et al. Viral hepatitis and HIV co-infection. Antiviral Res. 2010;85:303-315.
23 Graham CS, Baden LR, Yu E, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis. 2001;33:562-569.
24 Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf, 2009.
25 Choi AI, Rodriguez RA, Bacchetti P, et al. Racial differences in end-stage renal disease rates in HIV infection versus diabetes. J Am Soc Nephrol. 2007;18:2968-2974.
26 Lucas GM, Lau B, Atta MG, et al. Chronic kidney disease incidence, and progression to end-stage renal disease, in HIV-infected individuals: a tale of two races. J Infect Dis. 2008;197:1548-1557.
27 Winston JA. HIV and CKD epidemiology. Adv Chronic Kidney Dis. 2010;17:19-25.
28 Croda J, Croda MG, Neves A, et al. Benefit of antiretroviral therapy on survival of human immunodeficiency virus-infected patients admitted to an intensive care unit. Crit Care Med. 2009;37:1605-1611.
29 MacFadden DK, Edelson JD, Hyland RH, et al. Corticosteroids as adjunctive therapy in treatment of Pneumocystis carinii pneumonia in patients with acquired immunodeficiency syndrome. Lancet. 1987;1:1477-1479.
30 Bozzette SA, Sattler FR, Chiu J, et al. A controlled trial of early adjunctive treatment with corticosteroids for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. California Collaborative Treatment Group. N Engl J Med. 1990;323:1451-1457.
31 Miller RF, Allen E, Copas A, et al. Improved survival for HIV infected patients with severe Pneumocystis jirovecii pneumonia is independent of highly active antiretroviral therapy. Thorax. 2006;61:716-721.
32 Walzer PD, Evans HE, Copas AJ, et al. Early predictors of mortality from Pneumocystis jirovecii pneumonia in HIV-infected patients: 1985-2006. Clin Infect Dis. 2008;46:625-633.
33 Davis JL, Morris A, Kallet RH, et al. Low tidal volume ventilation is associated with reduced mortality in HIV-infected patients with acute lung injury. Thorax. 2008;63:988-993.
34 Phair J, Munoz A, Detels R, et al. The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. Multicenter AIDS Cohort Study Group. N Engl J Med. 1990;322:161-165.
35 Stansell JD, Osmond DH, Charlebois E, et al. Predictors of Pneumocystis carinii pneumonia in HIV-infected persons. Pulmonary Complications of HIV Infection Study Group. Am J Respir Crit Care Med. 1997;155:60-66.
36 Selwyn PA, Pumerantz AS, Durante A, et al. Clinical predictors of Pneumocystis carinii pneumonia, bacterial pneumonia and tuberculosis in HIV-infected patients. AIDS. 1998;12:885-893.
37 Kaplan JE, Benson C, Holmes KH, et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep. 2009;58:1-207. quiz CE201-204
38 Hardak E, Brook O, Yigla M. Radiological features of Pneumocystis jirovecii pneumonia in immunocompromised patients with and without AIDS. Lung. 2010;188:159-163.
39 Hidalgo A, Falco V, Mauleon S, et al. Accuracy of high-resolution CT in distinguishing between Pneumocystis carinii pneumonia and non-Pneumocystis carinii pneumonia in AIDS patients. Eur Radiol. 2003;13:1179-1184.
40 Boiselle PM, Tocino I, Hooley RJ, et al. Chest radiograph interpretation of Pneumocystis carinii pneumonia, bacterial pneumonia, and pulmonary tuberculosis in HIV-positive patients: accuracy, distinguishing features, and mimics. J Thorac Imaging. 1997;12:47-53.
41 Hopewell PC. Pneumocystis carinii pneumonia: diagnosis. J Infect Dis. 1988;157:1115-1119.
42 Golden JA, Hollander H, Stulbarg MS, et al. Bronchoalveolar lavage as the exclusive diagnostic modality for Pneumocystis carinii pneumonia. A prospective study among patients with acquired immunodeficiency syndrome. Chest. 1986;90:18-22.
43 Meduri GU, Stover DE, Greeno RA, et al. Bilateral bronchoalveolar lavage in the diagnosis of opportunistic pulmonary infections. Chest. 1991;100:1272-1276.
44 Cadranel J, Gillet-Juvin K, Antoine M, et al. Site-directed bronchoalveolar lavage and transbronchial biopsy in HIV-infected patients with pneumonia. Am J Respir Crit Care Med. 1995;152:1103-1106.
45 Helweg-Larsen J, Benfield T, Atzori C, et al. Clinical efficacy of first- and second-line treatments for HIV-associated Pneumocystis jirovecii pneumonia: a tri-centre cohort study. J Antimicrob Chemother. 2009;64:1282-1290.
46 Rabaud C, Charreau I, Izard S, et al. Adverse reactions to cotrimoxazole in HIV-infected patients: predictive factors and subsequent HIV disease progression. Scand J Infect Dis. 2001;33:759-764.
47 Hardy WD, Feinberg J, Finkelstein DM, et al. A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trials Group Protocol 021. N Engl J Med. 1992;327:1842-1848.
48 Schneider MM, Hoepelman AI, Eeftinck Schattenkerk JK, et al. A controlled trial of aerosolized pentamidine or trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection. The Dutch AIDS Treatment Group. N Engl J Med. 1992;327:1836-1841.
49 Decker CF, Masur H. Pneumonia in AIDS patients in the critical care unit. Crit Care Clin. 1998;14:135-157.
50 Klein NC, Duncanson FP, Lenox TH, et al. Trimethoprim-sulfamethoxazole versus pentamidine for Pneumocystis carinii pneumonia in AIDS patients: results of a large prospective randomized treatment trial. AIDS. 1992;6:301-305.
51 Sattler FR, Cowan R, Nielsen DM, et al. Trimethoprim-sulfamethoxazole compared with pentamidine for treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A prospective, noncrossover study. Ann Intern Med. 1988;109:280-287.
52 Masur H. Prevention and treatment of Pneumocystis pneumonia. N Engl J Med. 1992;327:1853-1860.
53 Benfield T, Atzori C, Miller RF, et al. Second-line salvage treatment of AIDS-associated Pneumocystis jirovecii pneumonia: a case series and systematic review. J Acquir Immune Defic Syndr. 2008;48:63-67.
54 Briel M, Boscacci R, Furrer H, et al. Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV infection: a meta-analysis of randomised controlled trials. BMC Infect Dis. 2005;5:101.
55 Lane BR, Ast JC, Hossler PA, et al. Dihydropteroate synthase polymorphisms in Pneumocystis carinii. J Infect Dis. 1997;175:482-485.
56 Ma L, Borio L, Masur H, et al. Pneumocystis carinii dihydropteroate synthase but not dihydrofolate reductase gene mutations correlate with prior trimethoprim-sulfamethoxazole or dapsone use. J Infect Dis. 1999;180:1969-1978.
57 Kazanjian P, Locke AB, Hossler PA, et al. Pneumocystis carinii mutations associated with sulfa and sulfone prophylaxis failures in AIDS patients. AIDS. 1998;12:873-878.
58 Helweg-Larsen J, Benfield TL, Eugen-Olsen J, et al. Effects of mutations in Pneumocystis carinii dihydropteroate synthase gene on outcome of AIDS-associated P. carinii pneumonia. Lancet. 1999;354:1347-1351.
59 Navin TR, Beard CB, Huang L, et al. Effect of mutations in Pneumocystis carinii dihydropteroate synthase gene on outcome of P. carinii pneumonia in patients with HIV-1: a prospective study. Lancet. 2001;358:545-549.
60 Crothers K, Beard CB, Turner J, et al. Severity and outcome of HIV-associated Pneumocystis pneumonia containing Pneumocystis jirovecii dihydropteroate synthase gene mutations. AIDS. 2005;19:801-805.
61 Shelhamer JH, Ognibene FP, Macher AM, et al. Persistence of Pneumocystis carinii in lung tissue of acquired immunodeficiency syndrome patients treated for Pneumocystis pneumonia. Am Rev Respir Dis. 1984;130:1161-1165.
62 Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. N Engl J Med. 2000;342:1301-1308.
63 Confalonieri M, Calderini E, Terraciano S, et al. Noninvasive ventilation for treating acute respiratory failure in AIDS patients with Pneumocystis carinii pneumonia. Intensive Care Med. 2002;28:1233-1238.
64 Chattha G, Arieff AI, Cummings C, et al. Lactic acidosis complicating the acquired immunodeficiency syndrome. Ann Intern Med. 1993;118:37-39.
65 Freiman JP, Helfert KE, Hamrell MR, et al. Hepatomegaly with severe steatosis in HIV-seropositive patients. AIDS. 1993;7:379-385.
66 Lonergan JT, Behling C, Pfander H, et al. Hyperlactatemia and hepatic abnormalities in 10 human immunodeficiency virus-infected patients receiving nucleoside analogue combination regimens. Clin Infect Dis. 2000;31:162-166.
67 Thoden J, Lebrecht D, Venhoff N, et al. Highly active antiretroviral HIV therapy-associated fatal lactic acidosis: quantitative and qualitative mitochondrial DNA lesions with mitochondrial dysfunction in multiple organs. AIDS. 2008;22:1093-1094.
68 Imhof A, Ledergerber B, Gunthard HF, et al. Risk factors for and outcome of hyperlactatemia in HIV-infected persons: is there a need for routine lactate monitoring? Clin Infect Dis. 2005;41:721-728.
69 Miller KD, Cameron M, Wood LV, et al. Lactic acidosis and hepatic steatosis associated with use of stavudine: report of four cases. Ann Intern Med. 2000;133:192-196.
70 Marceau G, Sapin V, Jacomet C, et al. Frequency, risk factors, and outcome of hyperlactatemia in HIV-positive persons: implications for the management of treated patients. Clin Chem. 2003;49:1154-1162.
71 Bonnet F, Bonarek M, Morlat P, et al. Risk factors for lactic acidosis in HIV-infected patients treated with nucleoside reverse-transcriptase inhibitors: a case-control study. Clin Infect Dis. 2003;36:1324-1328.
72 Claessens YE, Cariou A, Monchi M, et al. Detecting life-threatening lactic acidosis related to nucleoside-analog treatment of human immunodeficiency virus-infected patients, and treatment with L-carnitine. Crit Care Med. 2003;31:1042-1047.
73 Brinkman K, Kakuda TN. Mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors: a looming obstacle for long-term antiretroviral therapy? Curr Opin Infect Dis. 2000;13:5-11.
74 Fouty B, Frerman F, Reves R. Riboflavin to treat nucleoside analogue-induced lactic acidosis. Lancet. 1998;352:291-292.
75 Luzzati R, Del Bravo P, Di Perri G, et al. Riboflavine and severe lactic acidosis. Lancet. 1999;353:901-902.
76 Shelburne SA3rd, Hamill RJ, Rodriguez-Barradas MC, et al. Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy. Medicine (Baltimore). 2002;81:213-227.
77 Komanduri KV, Viswanathan MN, Wieder ED, et al. Restoration of cytomegalovirus-specific CD4+ T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1. Nat Med. 1998;4:953-956.
78 Narita M, Ashkin D, Hollender ES, et al. Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. Am J Respir Crit Care Med. 1998;158:157-161.
79 Muller M, Wandel S, Colebunders R, et al. Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect Dis. 2010;10:251-261.
80 Mori S, Polatino S, Estrada YM, et al. Pneumocystis-associated organizing pneumonia as a manifestation of immune reconstitution inflammatory syndrome in an HIV-infected individual with a normal CD4+ T-cell count following antiretroviral therapy. Int J STD AIDS. 2009;20:662-665.
81 Klotz SA, Aziz Mohammed A, Girmai Woldemichael M, et al. Immune reconstitution inflammatory syndrome in a resource-poor setting. J Int Assoc Physicians AIDS Care (Chic Ill). 2009;8:122-127.
82 Wislez M, Bergot E, Antoine M, et al. Acute respiratory failure following HAART introduction in patients treated for Pneumocystis carinii pneumonia. Am J Respir Crit Care Med. 2001;164:847-851.
83 Zolopa A, Andersen J, Powderly W, et al. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PLoS One. 2009;4:e5575.
84 Morris A, Wachter RM, Luce J, et al. Improved survival with highly active antiretroviral therapy in HIV-infected patients with severe Pneumocystis carinii pneumonia. AIDS. 2003;17:73-80.
85 Vincent B, Timsit JF, Auburtin M, et al. Characteristics and outcomes of HIV-infected patients in the ICU: impact of the highly active antiretroviral treatment era. Intensive Care Med. 2004;30:859-866.
86 Casalino E, Mendoza-Sassi G, Wolff M, et al. Predictors of short- and long-term survival in HIV-infected patients admitted to the ICU. Chest. 1998;113:421-429.
87 Radhi S, Alexander T, Ukwu M, et al. Outcome of HIV-associated Pneumocystis pneumonia in hospitalized patients from 2000 through 2003. BMC Infect Dis. 2008;8:118.
88 Huang L, Quartin A, Jones D, et al. Intensive care of patients with HIV infection. N Engl J Med. 2006;355:173-181.
89 Grunfeld C, Kotler DP, Hamadeh R, et al. Hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med. 1989;86:27-31.
90 Hommes MJ, Romijn JA, Endert E, et al. Insulin sensitivity and insulin clearance in human immunodeficiency virus-infected men. Metabolism. 1991;40:651-656.
91 Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 1998;12:F51-F58.
92 Brown TT, Cole SR, Li X, et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med. 2005;165:1179-1184.
93 Holmberg SD, Moorman AC, Williamson JM, et al. Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet. 2002;360:1747-1748.
94 Sabin CA, Worm SW, Weber R, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet. 2008;371:1417-1426.
95 Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS. 2008;22:F17-F24.
96 Bozzette SA, Ake CF, Tam HK, et al. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med. 2003;348:702-710.
97 Boccara F, Cohen A, Di Angelantonio E, et al. Coronary artery bypass graft in HIV-infected patients: a multicenter case control study. Curr HIV Res. 2008;6:59-64.
98 Sonino N. The use of ketoconazole as an inhibitor of steroid production. N Engl J Med. 1987;317:812-818.
99 Grinspoon SK, Bilezikian JP. HIV disease and the endocrine system. N Engl J Med. 1992;327:1360-1365.
100 Smith GH. Treatment of infections in the patient with acquired immunodeficiency syndrome. Arch Intern Med. 1994;154:949-973.
101 Marik PE, Kiminyo K, Zaloga GP. Adrenal insufficiency in critically ill patients with human immunodeficiency virus. Crit Care Med. 2002;30:1267-1273.
102 Marik PE, Pastores SM, Annane D, et al. Recommendations for the diagnosis and management of corticosteroid insufficiency in critically ill adult patients: consensus statements from an international task force by the American College of Critical Care Medicine. Crit Care Med. 2008;36:1937-1949.
